Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Completed EARLY PHASE1 INTERVENTIONAL NCT05125718

Clinical and Metagenomic Investigation of Antimicrobial Peptide Gel in Periodontal Treatment.

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

Background and objective(s): Periodontitis is initiated by a dysbiotic host-microbe relationship. Standard periodontal treatment involves oral hygiene education, mechanical debridement and periodic follow-ups with the aims of pocket closure and maintaining a symbiotic microbial community. Nonetheless, this therapy alone may fail due to the limitations of mechanical instrumentation. The use of antimicrobial in combination to subgingival debridement has been proposed for initial and recurrent periodontitis to enhance the effectiveness of mechanical instrumentation. Antimicrobial peptide (AMP) comprised of a wide range of peptide, was found naturally in various life forms or manufactured as a synthetic compound. This study was conducted to evaluate the use of AMP as an adjunct to non-surgical periodontal treatment in terms of clinical and microbiological outcomes. Hypothesis • There are changes in clinical periodontal parameters and subgingival microbial profile following treatment with locally delivered synthetic AMP.

Detailed Description

study design: This was a split-mouth randomised pilot study of a 3-months follow-up. Sample size calculation: The sample size was calculated using G\*Power software version 3.1.9.4 (Franz Faul, Universitat Kiel, Germany). Estimation of sample size was based on the mean and standard deviation of CAL between the test and control group of previous publication (Singh et al., 2018). Four samples in each group (test and control) were required to achieve 80% power at a significant level of 5%. Randomisation: The random allocation sequence was generated by another person who was not directly involved in the study using a Research Randomizer tools (https://www.randomizer.org/). Periodontal sites of each patient were randomised at a split mouth level (left or right halves of the dentition) to one of the two treatment groups. Allocated treatments were inserted into an opaque envelop. Treatment allocation was concealed from the clinician and only revealed once subgingival debridement was completed. intervention: At baseline, clinical measurement was recorded and target sites (sites with PPD ≥6mm) were identified. subgingival plaque were collected at target sites. The same clinician performed full mouth scaling and subgingival debridement, coupled with standardised oral hygiene instruction for all subjects. Upon the completion of treatment, second clinician applied the treatments according to the randomisation. * Test group: Subgingival instrumentation followed by Antimcrobial peptide gel (AMP) application in all target sites. * Control group: Subgingival instrumentation and normal saline irrigation in all target sites. Test and control intervention will be repeated for another 2 applications at an interval of 3 days. Subjects were re-examined and plaque sampling will be repeated at 6 weeks and 12 weeks. statistical analysis: Clinical parameters were reported as mean and standard deviation. P-value \<0.05 was considered statistically significant. intergroup and intragroup comparison of mean bleeding score, pocket depth, clinical attachment level will be conducted using SPSS software. For the metagenomic data, alpha and beta diversity were computed using QIIME 2. The difference in the relative abundance of individual genus over time will be analysed.

Interventions

Name: 0.85% synthetic antimicrobial peptide TAPS-18
Type: DRUG
Description: commercially available synthetic antimicrobial peptide gel for periodontal disease treatment
Name: 0.9% normal saline
Type: DRUG
Description: commercially available normal saline Sodium Chloride irrigation solution

Primary Outcomes

Measure: clinical measurement of pocket depth (mm)
TimeFrame: 6 weeks and 12 weeks
Description: changes in pocket depth after the test and control intervention. pocket depth is measured from the gingival margin to base of pocket using UNC-15 probe
Measure: clinical measurement of clinical attachment level (mm)
TimeFrame: 6 weeks and 12 weeks
Description: changes in clinical attachment level after the test and control intervention. clinical attachment level is measured from cemento-enamel junction to base of pocket using UNC-15 probe.
Measure: metagenomic analysis of the relative abundance (%) of bacterial from subgingival plaque
TimeFrame: 6 weeks and 12 weeks
Description: changes in relative abundance of bacterial after the test and control intervention is measured by the metagenomic analysis using subgingival plaque

Trial Information

NCT ID

NCT05125718

Status

Completed

Study Type

INTERVENTIONAL

Phases

EARLY PHASE1

Sponsor

University of Malaya

Last Updated

December 15, 2025